GlaxoSmithKline's Q1 revenue is 7.63 billion pounds, estimated at 7.61 billion pounds.

Adjusted earnings per share for the first quarter were 46.5 pence, compared to an estimate of 43.2 pence. GlaxoSmithKline reaffirmed its 2026 guidance and 2031 sales outlook. GlaxoSmithKline continues to expect full-year sales (at constant exchange rates) to grow by 3% to 5%. GlaxoSmithKline continues to expect full-year adjusted earnings per share to grow by 7% to 9%. GlaxoSmithKline continues to expect full-year adjusted operating profit to grow by 7% to 9%. GlaxoSmithKline still expects 2031 sales to exceed 40 billion pounds.